Clinical trials: Dose Finding Study
Male Erectile Dysfunction
Phase II Trial of SK3530 in Erectile Dysfunction
This study was designed to evaluate the efficacy and safety of the SK3530 tablet and to find the optimal dose and dosage schedule after oral administration to patients with erectile dysfunction.
- Trial name
- NCT00351065
- Testing
- SK3530
- Volunteers
- 120 people
- Sponsor
- SK Chemicals Co., Ltd.
Primary Sclerosing Cholangitis (PSC)
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
This was a phase 2, double-blind (DB), placebo-controlled trial in participants with primary sclerosing cholangitis to evaluate the effect of obeticholic acid on liver biochemistry, in particular, serum alkaline phosphatase; and…
- Trial name
- AESOP (NCT02177136)
- Testing
- Obeticholic Acid (OCA)
- Where
- 36 sites in United States, Italy
- Volunteers
- 77 people
- Sponsor
- Intercept Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-1-REF (NCT06215911)
- Testing
- Tovinontrine (CRD-750)
- Where
- 139 sites in United States, Australia and 17 more
- Volunteers
- 557 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Advanced Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
- Trial name
- NCT01131364
- Testing
- F16IL2 in combination with doxorubicin
- Where
- 5 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Type 2 Diabetes Mellitus
Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the clinical efficacy and safety of SK-0403 in patients with Type2 Diabetes Mellitus
- Trial name
- NCT00532506
- Testing
- SK-0403
- Where
- 10 sites in Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Type 2 Diabetes
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
- Trial name
- NCT01169090
- Testing
- SK-0403, Sitagliptin
- Where
- 40 sites in United States
- Volunteers
- 620 people
- Sponsor
- Kowa Research Institute, Inc.
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Glioma
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
- Trial name
- NCT00526812
- Testing
- RTA 744, RTA 744 injection
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Biogen
Healthy Volunteer
A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
In this study, researchers will learn how the heart reacts to multiple doses of BIIB091 in healthy participants. In previous studies looking at BIIB091, researchers have found that a certain range of doses can cause changes in…
- Trial name
- NCT06574828
- Testing
- BIIB091, Moxifloxacin
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Biogen
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA
Neoplasms
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate.
- Trial name
- NCT03449381
- Testing
- BI 907828
- Where
- 27 sites in United States, Belgium and 9 more
- Volunteers
- 266 people
- Sponsor
- Boehringer Ingelheim
Muscular Dystrophy, Duchenne
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram [mg/kg] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will…
- Trial name
- MIS51ON (NCT03992430)
- Testing
- Eteplirsen
- Where
- 59 sites in United States, Colombia and 24 more
- Volunteers
- 160 people
- Sponsor
- Sarepta Therapeutics, Inc.
Colonoscopy
Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy
This is a phase II, two-part, multiple-dose, dose-finding, single-blind study in adult participants undergoing elective colonoscopy for screening or diagnostic purposes.
- Trial name
- ABP-700 (NCT02800590)
- Testing
- ABP-700
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- The Medicines Company
Type 2 Diabetes (T2D)
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes.
- Trial name
- NCT06542874
- Testing
- NNC0487-0111 subcutanous, NNC0487-0111 oral
- Where
- 137 sites in United States, Bulgaria and 9 more
- Volunteers
- 448 people
- Sponsor
- Novo Nordisk A/S
Advanced Solid Tumors
Study With Atu027 in Patients With Advanced Solid Cancer
This is a phase I, prospective, open-label, single center, dose finding study with Atu027 (an siRNA formulation) given as single treatment followed by repeated treatment (repeated treatment phase: 8 treatments within 4 weeks) as…
- Trial name
- NCT00938574
- Testing
- Atu027
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Silence Therapeutics GmbH
Prevention of Postoperative Nausea and Vomiting
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for…
- Trial name
- NCT07709897
- Testing
- HRS5580 for injection combined with palonosetron hydrochloride;, HRS5580 for injection combined with palonosetron hydrochloride, HRS5580 for injection blank preparation combined with palonosetron hydrochloride
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Haemophilia A
Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.
Primary efficacy endpoint: To study whether there is a difference in the length of the bleeding free periods between infusion of FVIII that is reconstituted with 22.1, 12.6, or 4.2 mg of pegylated liposomes per kg bwt compared…
- Trial name
- NCT00245297
- Testing
- Kogenate FS, reconstituted in a suspension of liposomes
- Where
- 3 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Recoly N.V.
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.